Affinity Asset Advisors, LLC Celldex Therapeutics, Inc. Transaction History

Affinity Asset Advisors, LLC

$579 Million
Q3 2024

A detailed history of Affinity Asset Advisors, LLC transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 125,000 shares of CLDX stock, worth $3.1 Million. This represents 0.73% of its overall portfolio holdings.

Number of Shares

125,000

Previous 475,400 73.71%

Holding current value

$3.1 Million

Previous $17.6 Million 75.87%

% of portfolio

0.73%

Previous 2.39%

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$32.06 - $44.56 $11.2 Million - $15.6 Million	-350,400 Reduced 73.71%	125,000 $4.25 Million
Q2 2024 Aug 14, 2024	SELL	$32.76 - $42.56 $1.13 Million - $1.47 Million	-34,600 Reduced 6.78%	475,400 $17.6 Million
Q1 2024 May 14, 2024	BUY	$35.22 - $51.88 $3.87 Million - $5.71 Million	110,000 Added 27.5%	510,000 $21.4 Million
Q4 2023 Feb 13, 2024	BUY	$22.61 - $40.65 $5.65 Million - $10.2 Million	250,000 Added 166.67%	400,000 $15.9 Million
Q3 2023 Nov 14, 2023	BUY	$25.45 - $37.46 $1.6 Million - $2.36 Million	62,969 Added 72.35%	150,000 $4.13 Million
Q2 2023 Aug 14, 2023	BUY	$30.29 - $38.28 $1.12 Million - $1.42 Million	37,031 Added 74.06%	87,031 $2.95 Million
Q1 2023 May 15, 2023	SELL	$34.78 - $47.43 $2.09 Million - $2.85 Million	-60,000 Reduced 54.55%	50,000 $1.8 Million
Q4 2022 Feb 13, 2023	BUY	$27.78 - $45.38 $833,400 - $1.36 Million	30,000 Added 37.5%	110,000 $4.9 Million
Q3 2022 Nov 14, 2022	BUY	$22.7 - $37.57 $908,000 - $1.5 Million	40,000 Added 100.0%	80,000 $2.25 Million
Q2 2022 Aug 12, 2022	SELL	$20.5 - $37.33 $1.74 Million - $3.17 Million	-85,000 Reduced 68.0%	40,000 $1.08 Million
Q1 2022 May 13, 2022	BUY	$27.64 - $39.32 $691,000 - $983,000	25,000 Added 25.0%	125,000 $4.26 Million
Q4 2021 Feb 11, 2022	BUY	$35.68 - $56.27 $2.14 Million - $3.37 Million	59,846 Added 149.04%	100,000 $3.86 Million
Q3 2021 Nov 12, 2021	SELL	$28.95 - $55.99 $285,041 - $551,277	-9,846 Reduced 19.69%	40,154 $2.17 Million
Q2 2021 Aug 13, 2021	SELL	$20.71 - $35.37 $1.66 Million - $2.83 Million	-80,000 Reduced 61.54%	50,000 $1.67 Million
Q1 2021 May 14, 2021	BUY	$16.19 - $29.91 $890,450 - $1.65 Million	55,000 Added 73.33%	130,000 $2.68 Million
Q4 2020 Feb 12, 2021	BUY	$14.99 - $22.75 $1.12 Million - $1.71 Million	75,000 New	75,000 $1.31 Million

Others Institutions Holding CLDX

# of Institutions

207

Shares Held

67.3M

Call Options Held

1.69M

Put Options Held

980K

View Full List

About Celldex Therapeutics, Inc.

Ticker CLDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,772,400
Market Cap $1.16B
Description
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...

More about CLDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Affinity Asset Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Affinity Asset Advisors, LLC with notifications on news.

Account

Affinity Asset Advisors, LLC Celldex Therapeutics, Inc. Transaction History